Lincoln Pharmaceuticals has reported total income of Rs.82.11 crores during the period ended March 31, 2021 as compared to Rs.115.47 crores during the period ended December 31, 2020. The company reported total income of Rs.82.65 crores during the period ended March 31, 2020.

The company has posted net profit of Rs.12.57 crores for the period ended March 31, 2021 as against net profit of Rs.13.48 crores for the period ended December 31, 2020. It posted net profit of Rs.8.94 crores for the period ended March 31, 2020.

Lincoln Pharmaceuticals has reported total income of Rs.429.84 crores during the 12 months period ended March 31, 2021 as compared to Rs.397.53 crores during the 12 months period ended March 31, 2020.

The company has posted net profit of Rs.62.22 crores for the 12 months period ended March 31, 2021 as against net profit of Rs.51.43 crores for the 12 months period ended March 31, 2020.

Commenting on the results and performance, Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Limited, said, "Company's performance during the quarter and full year has been quite robust and considering that have recommended dividend of Rs. 1.50 per share. Company is growing strength to strength, delivering robust operational and financial performance maintaining healthy growth in revenue, margins and profitability. We expect the growth momentum to continue in coming years. Our strategic growth initiatives, product and geographical expansion, operational efficiency are likely to maximise value for all stakeholders in the near to medium term."

Lincoln Pharmaceuticals is witnessing good traction in the export business, which is expected to get further boost once EU operations begins. The company plans to enter the EU markets in FY22 with its dermatology, gastro and pain management products. Company currently exports to more than 60 countries and plans to expand to 90 plus countries. For the next phase of growth, company is building a strong portfolio in lifestyle and chronic segment especially. dermatology, gastro and pain management to complement its strong presence in acute segment.